Fayerweather Charles bought a new stake in The Medicines Company (NASDAQ:MDCO) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,750 shares of the company’s stock, valued at approximately $237,000.

A number of other institutional investors also recently modified their holdings of MDCO. Vivo Capital LLC acquired a new stake in The Medicines in the second quarter valued at approximately $24,399,000. Balyasny Asset Management LLC boosted its position in The Medicines by 132.1% in the second quarter. Balyasny Asset Management LLC now owns 129,837 shares of the company’s stock valued at $4,735,000 after buying an additional 534,837 shares in the last quarter. Vanguard Group Inc. boosted its position in The Medicines by 6.6% in the second quarter. Vanguard Group Inc. now owns 7,438,930 shares of the company’s stock valued at $271,297,000 after buying an additional 460,064 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in The Medicines in the second quarter valued at approximately $16,547,000. Finally, Renaissance Technologies LLC acquired a new stake in The Medicines in the second quarter valued at approximately $12,890,000.

MDCO traded up $0.64 during midday trading on Friday, hitting $55.01. The company had a trading volume of 857,700 shares, compared to its average volume of 1,539,007. The Medicines Company has a 52 week low of $16.69 and a 52 week high of $58.48. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 21.45. The company has a market capitalization of $4.28 billion, a price-to-earnings ratio of -18.90 and a beta of 0.90. The stock’s 50 day moving average price is $52.53 and its 200 day moving average price is $40.30.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.12). During the same quarter in the previous year, the company earned ($0.70) EPS. Research analysts predict that The Medicines Company will post -3.4 EPS for the current year.

A number of analysts have weighed in on the stock. Citigroup lowered shares of The Medicines from a “buy” rating to a “neutral” rating and set a $55.00 target price on the stock. in a research report on Tuesday, September 17th. Chardan Capital set a $90.00 target price on shares of The Medicines and gave the company a “buy” rating in a research report on Monday, August 26th. BidaskClub lowered shares of The Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 2nd. JPMorgan Chase & Co. raised their target price on shares of The Medicines from $39.00 to $49.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Finally, ValuEngine lowered shares of The Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company. The Medicines has a consensus rating of “Buy” and a consensus price target of $70.77.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.

Recommended Story: Dow Jones Industrial Average (DJIA)

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.